Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
This 2021 commentary by Hadaschik and Herrmann discusses the findings of the VISION trial, which evaluated the efficacy of Lutetium-177-PSMA-617 (Lu-PSMA-617) in patients with metastatic castration-resistant prostate cancer (mCRPC). The VISION trial demonstrated that Lu-PSMA-617, when added to standard care, significantly improved both imaging-based progression-free survival (8.7 vs. 3.4 months)
June 26, 2025
No Comments